PreprintCited by 8,586SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Open access
Walls, Alexandra C., Park, Young-Jun, Tortorici, M. Alexandra, Wall, Abigail, McGuire, Andrew T., Veesler, David·2020·Cell

Abstract

SUMMARY: The recent emergence of a novel coronavirus associated with an ongoing outbreak of pneumonia (Covid-2019) resulted in infections of more than 72,000 people and claimed over 1,800 lives. Coronavirus spike (S) glycoprotein trimers promote entry into cells and are the main target of the humoral immune response. We show here that SARS-CoV-2 S mediates entry in VeroE6 cells and in BHK cells transiently transfected with human ACE2, establishing ACE2 as a functional receptor for this novel coronavirus. We further demonstrate that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, which correlates with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S 1 /S 2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and other SARS-related CoVs. We determined a cryo-electron microscopy structure of the SARS-CoV-2 S ectodomain trimer, demonstrating spontaneous opening of the receptor-binding domain, and providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal sera potently inhibited SARS-CoV-2 S-mediated entry into target cells, thereby indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2020.02.19.956581

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The SARS-CoV-2 Spike protein mediates binding of coronaviruses to ACE2 on the surface of various cell types including epithelial cells of the pulmonary alveolus.

    “The S protein mediates binding of coronaviruses to angiotensin converting enzyme 2 (ACE2) on the surface of various cell types including epithelial cells of the pulmonary alveolus (4–6).”

    From An <i>Alphavirus</i> -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates (2020) · cites this paper as [6]

    The Introduction and Results section “ACE2 Is an Entry Receptor for SARS-CoV-2” establish that SARS-CoV-2 spike binds ACE2 and can mediate entry into ACE2-expressing cells. The same Results section identifies ACE2 at the surface of type II pneumocytes—alveolar epithelial cells—but makes that statement about SARS-CoV, not SARS-CoV-2. The cited paper therefore does not directly establish SARS-CoV-2 spike binding on those lung cells. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Most neutralizing antibodies are molded based on epitopes of S protein in prefusion conformation, which is covered once the S protein acquires the postfusion conformation, thus reducing the production of neutralizing antibodies.

    “Most neutralizing antibodies are molded based on epitopes of S protein in prefusion conformation, which is covered once the S protein acquires the postfusion conformation, thus reducing the production of neutralizing antibodies.238”

    From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [238]

  • The S1/S2 cleavage site strategy employs direct deletion of the sequence Q677TNSPRRARYSV687 to Q677TILRYSV683 or mutation of amino acids (RRAR to GGSG) that prevent S protein cleavage in the host cell, thus maintaining its structural stability and inducing stronger immune responses.

    “The S1/S2 cleavage site strategy employs direct deletion of the sequence Q677TNSPRRARYSV687 in wild-type SARS-CoV-2 protein S to Q677TILRYSV683238 or mutation of amino acids (RRAR to GGSG)141 that ultimately prevent the S protein from cleavage in the host cell, thus maintaining its structural stability and inducing stronger immune responses.”

    From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [238]

  • BNT162b1 encodes a trimerized, secreted version of the spike protein's receptor-binding domain.

    “BNT162b1 encodes a trimerized, secreted version of the spike protein’s receptor-binding domain, whereas BNT162b2 encodes the full-length SARS-CoV-2 spike glycoprotein with two proline substitutions in the S2 subunit, which lock the protein in its prefusion conformation120,121.”
  • BNT162b2 encodes the full-length SARS-CoV-2 spike glycoprotein with two proline substitutions in the S2 subunit, which lock the protein in its prefusion conformation.

    “BNT162b1 encodes a trimerized, secreted version of the spike protein’s receptor-binding domain, whereas BNT162b2 encodes the full-length SARS-CoV-2 spike glycoprotein with two proline substitutions in the S2 subunit, which lock the protein in its prefusion conformation120,121.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D.
Affiliations
  • University of Washington (US)
  • Fred Hutch Cancer Center (US)
Corresponding author
Veesler, David
Venue
Cell
Publisher
openRxiv
Published
2020-02-20
Volume
181
Issue
2
Pages
281-292.e6
ISSN
0092-8674 (ISSN-L)
OpenAlex
W3009335299
Cited by
8,586
References
105
Citations by year
2026: 220 · 2025: 378 · 2024: 621 · 2023: 877 · 2022: 1524 · 2021: 2686 · 2020: 2265 · 2019: 3 · 2013: 1 · 2012: 2
FWCI
241.19
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • Burroughs Wellcome Fund
  • National Institutes of Health (1s10od023476-01)
  • National Institute of General Medical Sciences (R01GM120553)
  • National Institute of Allergy and Infectious Diseases (HHSN272201700059C)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords
SARS-CoV-2, spike protein, ACE2 receptor, receptor binding domain, furin cleavage site, viral entry, cross-neutralizing antibodies, SARS-CoV, vaccine design, antiviral agents, cryo-EM structure, antigenicity
MeSH terms
Betacoronavirus, Angiotensin-Converting Enzyme 2, SARS-CoV-2, Amino Acid Sequence, Antigens, Viral, Cell Line, Humans, Peptidyl-Dipeptidase A, Models, Molecular, Receptors, Virus, Cryoelectron Microscopy, Severe acute respiratory syndrome-related coronavirus, Virus Internalization, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review